We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PROMEGA

Promega has a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression,... read more Featured Products: More products

Download Mobile App




Intestinal Microbiota Determines the Risk of MDRO Acquisition

By LabMedica International staff writers
Posted on 10 Feb 2022
Print article
Image: The Quantus Fluorometer is a compact, dual-channel fluorometer designed to provide highly sensitive fluorescent detection when quantifying nucleic acids (Photo courtesy of Promega)
Image: The Quantus Fluorometer is a compact, dual-channel fluorometer designed to provide highly sensitive fluorescent detection when quantifying nucleic acids (Photo courtesy of Promega)

Colonization and infection by multidrug-resistant organisms (MDRO) remains a public health problem. This is particularly important in intensive care units (ICUs) where the risk of MDRO acquisition/colonization results from the selective pressure associated with prolonged broad-spectrum antibiotic treatment.

Control initiatives consist in detecting patients at high risk of MDRO acquisition, implementation of antibiotic stewardship programs, epidemiological surveillance to detect MDRO intestinal carriage, microbiological tests to rapidly identify MDRO and use of effective measures to reduce their nosocomial transmission.

Clinical Microbiologists at the Hospital Clínic de Barcelona (Barcelona, Spain) conducted a prospective study including patients admitted to a 12-bed ICU between July-December 2018. Rectal swabs to detect MDRO intestinal colonization were obtained at ICU admission and weekly thereafter during ICU-stay. Patients were classified into three groups according to MDRO colonization status. Control group included patients who were not colonized by MDROs at ICU admission and did not get colonized during ICU stay.

The team extracted DNA using the PureLink Microbiome DNA Purification kit (Invitrogen, Carlsbad, MA, USA) and quantified using Quantus Flurometer (Promega, Madison, WI, USA). The 16S rRNA gene sequencing was performed on 138 rectal swabs from 62 patients using the sequenced using Illumina MiSeq platform (Illumina, San Diego, CA, USA). After sequence filtering and sample rarefaction alpha and beta diversity indices were obtained using QIIME2 and statistical analyses were performed.

The investigators reported that of the patients studied, 19/62 (30.65%) presented MDRO colonization at admission, 16/62 (25.81%) were colonized during stay and 27/62 (43.55%) were not colonized; 45/62 (72.58%) developed an infection and mortality was 29.03%. Higher bacterial diversity and abundance of Bacillales Family XI incertae sedis and Prevotella families were associated with lower risk of colonization by MDRO, infection and death while Enterococcaceae family was associated with increased risk of infection and death. The lasso regression and the multivariate analysis identified Family XI incertae sedis to be associated with lower risk of infection (OR=0.997) and microbial evenness index to be associated with lower mortality (OR=0.68) risk.

The authors concluded that microbial diversity and abundance of certain bacterial taxa could have prognostic value in patients admitted to a critical care unit. Larger perspective studies should address the value of these markers in clinical practice. The study was published on January 19, 2022 in the journal Clinical Microbiology and Infection.

Related Links:
Hospital Clínic de Barcelona 
Invitrogen 
Promega
Illumina 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.